Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Nonnekens, Julie, van Kranenburg, Melissa, Beerens, Cecile E.M.T., Suker, Mustafa, Doukas, Michael, van Eijck, Casper H.J., de Jong, Marion, van Gent, Dik C.
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997239/
https://ncbi.nlm.nih.gov/pubmed/27570553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.15311
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars